




PHARMACEUTICAL 2020

Clovis Oncology Inc.
Rank 301 of 358





RealRate

PHARMACEUTICAL 2020

Clovis Oncology Inc.
Rank 301 of 358



The relative strengths and weaknesses of Clovis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Clovis Oncology Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Clovis Oncology Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 178% points.

The company's Economic Capital Ratio, given in the ranking table, is -93%, being 129% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	366,468
Cost of Goods Sold	0
Intangible Assets	125,994
Liabilities, Current	133,084
Liabilities, Non-Current	0
Other Assets	161,855
Other Compr. Net Income	-231
Other Expenses	46,195
Other Liabilities	710,777
Other Net Income	-21,880
Other Revenues	143,006
Property and Equipment	15,287
Research and Development	292,586
Selling, General and Administrative Expense	182,769

Output Variable	Value in 1000 USD
Assets	669,604
Liabilities	843,861
Expenses	521,550
Revenues	143,006
Stockholders Equity	-174,257
Net Income	-400,424
Comprehensive Net Income	-400,540
Economic Capital Ratio	-93%